


Amendments to the Claims

The listing of claims will replace all prior versions and listing of claims in the application:


Listing of Claims:

5 Claim 1 (currently amended): A compound represented by the structural formula:



or a pharmaceutically acceptable salt or solvate of said compound, wherein:

10 R is H, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, alkenylalkyl, alkynylalkyl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl (including N-oxide of said heteroaryl), $-(CHR^5)_n$ -aryl, $-(CHR^5)_n$ -




15 15 wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclylalkyl, CF₃, OCF₃, CN, -OR⁵, -NR⁵R¹⁰, -C(R⁴R⁵)_p-R⁹, -N(R⁵)Boc, -(CR⁴R⁵)_pOR⁵, -C(O₂)R⁵, -C(O)R⁵, -C(O)NR⁵R¹⁰, -SO₃H, -SR¹⁰, -S(O₂)R⁷, -S(O₂)NR⁵R¹⁰, -N(R⁵)S(O₂)R⁷, -N(R⁵)C(O)R⁷ and -N(R⁵)C(O)NR⁵R¹⁰;

R² is selected from the group consisting of R⁹, alkyl, alkenyl, alkynyl,

25 CF₃, heterocyclyl, heterocyclylalkyl, halogen, haloalkyl, aryl, arylalkyl, heteroarylalkyl, alkynylalkyl, cycloalkyl, heteroaryl, alkyl substituted with 1-6 R⁹ groups which can be the same or different and are independently selected


from the list of R^9 shown below, aryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, aryl fused with an aryl or heteroaryl group, heteroaryl substituted with 1-3 aryl or heteroaryl

5 groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, heteroaryl fused



10 wherein one or more of the aryl and/or one or more of the heteroaryl in the above-noted definitions for R^2 can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, -CN, -OR⁵, -SR⁵, -S(O₂)R⁶, -S(O₂)NR⁵R⁶, -NR⁵R⁶, -C(O)NR⁵R⁶, CF₃,
15 alkyl, aryl and OCF₃;

R^3 is selected from the group consisting of H, halogen, -NR⁵R⁶, -OR⁶, -SR⁶, -C(O)N(R⁵R⁶), alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, heteroaryl and heteroarylalkyl,



20 wherein each of said alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, heteroaryl and heteroarylalkyl for R^3 and the heterocyclyl moieties whose structures are shown immediately above for R^3 can be unsubstituted or optionally independently substituted with one or more
25 moieties which can be the same or different, each moiety being independently

selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF_3 , CN , $-\text{OCF}_3$, $-(\text{CR}^4\text{R}^5)_p\text{OR}^5$, $-\text{OR}^5$, $-\text{NR}^5\text{R}^6$, $-(\text{CR}^4\text{R}^5)_p\text{NR}^5\text{R}^6$, $-\text{C}(\text{O}_2)\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^6$, $-\text{SR}^6$, $-\text{S}(\text{O}_2)\text{R}^6$, $-\text{S}(\text{O}_2)\text{NR}^5\text{R}^6$, $-\text{N}(\text{R}^5)\text{S}(\text{O}_2)\text{R}^7$, $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^7$ and $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{NR}^5\text{R}^6$, with the proviso that no carbon adjacent to a nitrogen atom

5 on a heterocycl ring carries a $-\text{OR}^5$ moiety;

R^4 is H, halo or alkyl;

R^5 is H, alkyl, aryl or cycloalkyl;

R^6 is selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, cycloalkyl, heterocycl, heterocyclalkyl, heteroaryl,

10 and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocycl, heterocyclalkyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclalkyl, CF_3 ,

15 OCF_3 , CN , $-\text{OR}^5$, $-\text{NR}^5\text{R}^{10}$, $-\text{C}(\text{R}^4\text{R}^5)_p\text{R}^9$, $-\text{N}(\text{R}^5)\text{Boc}$, $-(\text{CR}^4\text{R}^5)_p\text{OR}^5$, $-\text{C}(\text{O}_2)\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{10}$, $-\text{SO}_3\text{H}$, $-\text{SR}^{10}$, $-\text{S}(\text{O}_2)\text{R}^7$, $-\text{S}(\text{O}_2)\text{NR}^5\text{R}^{10}$, $-\text{N}(\text{R}^5)\text{S}(\text{O}_2)\text{R}^7$, $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^7$ and $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{NR}^5\text{R}^{10}$;

R^{10} is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocycl, heterocyclalkyl, heteroaryl, and heteroarylalkyl,

20 wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocycl, heterocyclalkyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclalkyl, CF_3 , OCF_3 , CN , $-\text{OR}^5$, $-\text{NR}^4\text{R}^5$, $-\text{C}(\text{R}^4\text{R}^5)_p\text{R}^9$, $-\text{N}(\text{R}^5)\text{Boc}$, $-(\text{CR}^4\text{R}^5)_p\text{OR}^5$, $-\text{C}(\text{O}_2)\text{R}^5$, $-\text{C}(\text{O})\text{NR}^4\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{SO}_3\text{H}$, $-\text{SR}^5$, $-\text{S}(\text{O}_2)\text{R}^7$, $-\text{S}(\text{O}_2)\text{NR}^4\text{R}^5$, $-\text{N}(\text{R}^5)\text{S}(\text{O}_2)\text{R}^7$, $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^7$ and $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{NR}^4\text{R}^5$;

or optionally (i) R^5 and R^{10} in the moiety $-\text{NR}^5\text{R}^{10}$, or (ii) R^5 and R^6 in the moiety $-\text{NR}^5\text{R}^6$, may be joined together to form a cycloalkyl or

30 heterocycl moiety, with each of said cycloalkyl or heterocycl moiety being unsubstituted or optionally independently being substituted with one or more R^9 groups;

R^7 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkenyl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylalkenyl, and

heterocyclyl, wherein each of said alkyl, cycloalkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of

5 halogen, alkyl, aryl, cycloalkyl, CF_3 , OCF_3 , CN , $-\text{OR}^5$, $-\text{NR}^5\text{R}^{10}$, $-\text{CH}_2\text{OR}^5$, $-\text{C}(\text{O}_2)\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{10}$, $-\text{C}(\text{O})\text{R}^5$, $-\text{SR}^{10}$, $-\text{S}(\text{O}_2)\text{R}^{10}$, $-\text{S}(\text{O}_2)\text{NR}^5\text{R}^{10}$, $-\text{N}(\text{R}^5)\text{S}(\text{O}_2)\text{R}^{10}$, $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^{10}$ and $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{NR}^5\text{R}^{10}$;

R^8 is selected from the group consisting of R^6 , $-\text{OR}^6$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{10}$, $-\text{S}(\text{O}_2)\text{NR}^5\text{R}^{10}$, $-\text{C}(\text{O})\text{R}^7$, $-\text{C}(\text{=N-CN})\text{-NH}_2$, $-\text{C}(\text{=NH})\text{-NHR}^5$, heterocyclyl, and
10 $-\text{S}(\text{O}_2)\text{R}^7$;

R^9 is selected from the group consisting of halogen, $-\text{CN}$, $-\text{NR}^5\text{R}^{10}$, $-\text{C}(\text{O}_2)\text{R}^6$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{10}$, $-\text{OR}^6$, $-\text{SR}^6$, $-\text{S}(\text{O}_2)\text{R}^7$, $-\text{S}(\text{O}_2)\text{NR}^5\text{R}^{10}$, $-\text{N}(\text{R}^5)\text{S}(\text{O}_2)\text{R}^7$, $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^7$ and $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{NR}^5\text{R}^{10}$;


m is 0 to 4;

15 n is 1 to 4; and

p is 1 to 4,

with the proviso that when R^2 is phenyl, R^3 is not alkyl, alkynyl or halogen, and

that when R^2 is aryl, R is not $\overset{\S}{\text{---}}(\text{CHR}^5)_n\text{---NR}^5\text{R}^8$, and with the further proviso that when R is arylalkyl, then any heteroaryl substituent on the aryl of
20 said arylalkyl contains at least three heteroatoms, and with the additional proviso that the compound of the structural formula above excludes the following compounds:




Claim 2 (original): The compound of claim 1, wherein R is $-(CHR^5)_n$ -aryl,

5 $-(CHR^5)_n$ -heteroaryl, alkyl, cycloalkyl, heterocyclyl, or heteroarylalkyl (including N-oxide of said heteroaryl), wherein each of said alkyl, aryl, cycloalkyl, heterocyclyl and heteroaryl can be unsubstituted or optionally substituted with one or more moieties as stated in claim 1;

R^2 is halogen, alkyl, haloalkyl, CN, cycloalkyl, heterocyclyl or alkynyl;

10 R^3 is H, lower alkyl, aryl, heteroaryl, cycloalkyl, $-NR^5R^6$,



15 wherein said alkyl, aryl, heteroaryl, cycloalkyl and the heterocyclyl structures shown immediately above for R^3 are optionally substituted with one or more

moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, CF_3 , OCF_3 , lower alkyl, CN, $-\text{C}(\text{O})\text{R}^5$, $-\text{S}(\text{O}_2)\text{R}^5$, $-\text{C}(=\text{NH})-\text{NH}_2$, $-\text{C}(=\text{CN})-\text{NH}_2$, hydroxyalkyl, alkoxy carbonyl, $-\text{SR}^5$, and OR^5 , with the proviso that no carbon adjacent to a nitrogen atom on

5 a heterocyclyl ring carries a $-\text{OR}^5$ moiety;

R^4 is H or lower alkyl;

R^5 is H, lower alkyl or cycloalkyl;

n is 1 to 2; and


p is 1 or 2.

10 Claim 3 (original): The compound of claim 2, wherein R is hydroxyalkyl, $-(\text{CHR}^5)_n$ -aryl, or $-(\text{CHR}^5)_n$ -heteroaryl, wherein each of said aryl and heteroaryl is unsubstituted or substituted with one or more groups which can be the same or different, each group being independently selected from the group consisting of heteroaryl, amine, heterocyclyl, $-\text{C}(\text{O})\text{N}(\text{R}^5\text{R}^6)$, $-\text{S}(\text{O}_2)\text{R}^5$, $-\text{S}(\text{O}_2)\text{N}(\text{R}^5\text{R}^6)$, alkoxy and halo.

15

Claim 4 (original): The compound of claim 2, wherein R^2 is Br, Cl, CF_3 , CN, lower alkyl, cyclopropyl, alkynyl, alkyl substituted with $-\text{OR}^6$ or tetrahydrofuranyl.

Claim 5 (original): The compound of claim 2, wherein R^3 is H, lower alkyl, aryl, heteroaryl, cycloalkyl,



25 wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and the heterocyclyl structures shown immediately above for R^3 are optionally substituted with one or more moieties which moieties can be the same or different, each moiety

being independently selected from the group consisting of halogen, CF_3 , OCF_3 , lower alkyl, CN and OR^5 , with the proviso that no carbon adjacent to a nitrogen atom on a heterocycl ring carries a – OR^5 moiety.

Claim 6 (original): The compound of claim 2, wherein R^4 is H or lower alkyl.

5 Claim 7 (original): The compound of claim 2, wherein R^5 is H.

Claim 8 (original): The compound of claim 2, wherein n is 1.

Claim 9 (original): The compound of claim 1, wherein p is 1.

Claim 10 (original): The compound of claim 2, wherein R is benzyl or hydroxyalkyl.

10 Claim 11 (original): The compound of claim 2, wherein R is pyrid-3-ylmethyl, wherein said pyridyl may be unsubstituted or optionally independently substituted with one or more moieties as stated in claim 1.

Claim 12 (original): The compound of claim 2, wherein R is pyrid-4-ylmethyl, wherein said pyridyl may be unsubstituted or optionally independently substituted with one or more moieties as stated in claim 1.

15

Claim 13 (original): The compound 2, wherein R is the N-oxide of pyrid-2-ylmethyl, pyrid-3-ylmethyl, or pyrid-4-ylmethyl, wherein each of said pyridyl may be unsubstituted or optionally independently substituted with one or more moieties as stated in claim 1.

20 Claim 14 (original): The compound of claim 4, wherein said R^2 is Br.

Claim 15 (original): The compound of claim 4, wherein said R^2 is Cl.

Claim 16 (original): The compound of claim 4, wherein R^2 is ethyl.

Claim 17 (original): The compound of claim 4, wherein R^2 is cyclopropyl.

Claim 18 (original): The compound of claim 4, wherein R^2 is ethynyl.

25 Claim 19 (original): The compound of claim 2, wherein R^3 is lower alkyl, cycloalkyl, heterocycl, aryl or $-\text{N}(\text{R}^5\text{R}^6)$.

Claim 20 (original): The compound of claim 19, wherein R^3 is isopropyl.

Claim 21 (original): The compound of claim 19, wherein R^3 is cyclohexyl or norbornyl wherein each of said cyclohexyl or norbornyl can be unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of alkyl and hydroxyalkyl.

30 Claim 22 (original): The compound of claim 19, wherein R^3 is unsubstituted phenyl.

Claim 23 (original): The compound of claim 19, wherein R³ is a phenyl substituted with one or moieties which can be the same or different, each moiety being independently selected from the group consisting of F, Br, Cl and CF₃.

5 Claim 24 (original): The compound of claim 19, wherein R⁵ of said -N(R⁵R⁶) is H or hydroxyalkyl, and R⁶ of said -N(R⁵R⁶) is selected from the group consisting of alkyl, hydroxyalkyl, cycloalkyl and methylenedioxy, wherein each of said alkyl and cycloalkyl can be unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being

10 independently selected from the group consisting of amine, ethoxycarbonyl, amide, hydroxyalkyl, hydroxy,


Claim 25 (original): The compound of claim 19, wherein R⁵ and R⁶ of said -N(R⁵R⁶) are joined together to form a heterocyclyl moiety, wherein said heterocyclyl moiety can be unsubstituted or optionally independently


15 substituted with one or more groups which can be the same or different, each group being selected from the group consisting of hydroxyalkyl, amide, -C(O)R⁵, >C(CH₃)₂, -S(O₂)R⁵, -S(O₂)N(R⁵R⁶), -C(=NH)N(R⁵R⁶) and -C(=N-CN)N(R⁵R⁶).


Claim 26 (original): The compound of claim 25, wherein said heterocyclyl


20 moiety formed by R⁵ and R⁶ is a pyrrolidine or piperidine ring.


Claim 27 (currently amended): A compound of the formula:













































5


or a pharmaceutically acceptable salt or solvate thereof.


Claim 28 (currently amended): A compound of the formula:















or a pharmaceutically acceptable salt or solvate thereof.


Claim 29 (currently amended): A compound of the formula:












5 or a pharmaceutically acceptable salt or solvate thereof.

Claim 30 (currently amended): A compound of the formula:



5 or a pharmaceutically acceptable salt or solvate thereof.

Claim 31 (currently amended): A method of inhibiting one or more cyclin dependent kinases, comprising administering a therapeutically effective amount of at least one compound of claim 1 ~~to a patient in need of such inhibition~~.

10 Claim 32 (Currently amended): A method of treating one or more diseases associated with cyclin dependent kinase, comprising administering a therapeutically effective amount of at least one compound of claim 1 ~~to a patient in need of such treatment~~.

15 Claim 33 (original): The method of claim 32, wherein said cyclin dependent kinase is CDK2.

Claim 34 (original): The method of claim 32, wherein said cyclin dependent kinase is mitogen activated protein kinase (MAPK/ERK).

Claim 35 (original): The method of claim 32, wherein said cyclin dependent kinase is glycogen synthase kinase 3 (GSK3beta).

Claim 36 (original): The method of claim 32, wherein said disease is selected from the group consisting of:

5 cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

 leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins

10 lymphoma, hairy cell lymphoma and Burkett's lymphoma;

 acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

 fibrosarcoma, rhabdomyosarcoma;

 astrocytoma, neuroblastoma, glioma and schwannomas;

15 melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 37 (currently amended): A method of treating one or more diseases associated with cyclin dependent kinase, comprising administering to a
20 mammal in need of such treatment

 an amount of a first compound, which is a compound of claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof;

 and

25 an amount of at least one second compound, said second compound being an anti-cancer agent;

 wherein the amounts of the first compound and said second compound result in a therapeutic effect.

Claim 38 (original): The method of claim 37, further comprising radiation therapy.

30 Claim 39 (original): The method of claim 37, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123,

BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine,

5 Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -

10 Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide,

15 Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 40 (original): A pharmaceutical composition comprising a

20 therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

Claim 41 (original): The pharmaceutical composition of claim 38, additionally comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11,

25 irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan,

30 Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine,

Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone,

5 Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11,

10 10 Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 42 (original): A compound of claim 1 in purified form.

Claim 43 (new claim): A method of treating a cancer, comprising administering a therapeutically effective amount of at least one compound of claim 1.

Claim 44 (new claim): The method of claim 43, wherein said cancer is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's

30 sarcoma.

Claim 45 (new claim): A method of treating a cancer, comprising administering to a mammal in need of such treatment

an amount of a first compound, which is a compound of claim 1, or a pharmaceutically acceptable salt thereof;

and

an amount of at least one second compound, said second compound
5 being an anti-cancer agent;
wherein the amounts of the first compound and said second compound
result in a therapeutic effect.

Claim 46 (new claim): The method of claim 45, further comprising
radiation therapy.

10 Claim 47 (new claim): The method of claim 45, wherein said anti-cancer
agent is selected from the group consisting of a cytostatic agent, cisplatin,
doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar,
topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil,
methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336,
15 R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR,
Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard,
Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman,
Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine,
Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine,
20 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin,
leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine,
Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin,
Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide
17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone,
25 Fluoxymesterone, Dromostanolone propionate, Testolactone,
Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone,
Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,
Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide,
Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine,
30 Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11,
Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or
Hexamethylmelamine.